Biopharmaceutical company Pharming Group N.V. (Euronext Amsterdam:PHARM) (NASDAQ:PHAR) announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its supplemental New Drug Application for leniolisib in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).
The application has been granted Priority Review with a PDUFA target action date of 31 January 2026.
Pharming's submission is based on positive results from a multinational Phase III study showing improvements in lymphadenopathy and naïve B cell counts over 12 weeks, indicating correction of the underlying immune defect. Safety data from eight months of treatment were also included.
If approved, leniolisib would become the first and only treatment indicated for children under 12 with APDS globally. The therapy is marketed in the United States as Joenja and received FDA approval in March 2023 for patients aged 12 years and older.
Alto Neuroscience receives FDA Fast Track designation for ALTO-101
Calico Life Sciences' investigational treatment for ADPKD receives US FDA Fast Track Designation
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
Celltrion launches AVTOZMA IV in the United States following FDA approval
Vanda Pharmaceuticals agrees collaborative framework to resolve US FDA disputes
Microbot Medical secures first Japanese patent for Liberty robotic system following FDA clearance
Pharming receives FDA priority review for leniolisib in children with APDS
Renalytix submits CE Mark application for kidneyIntelX.dkd in Europe